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Background and Aims: Nonalcoholic Fatty Liver Disease (NAFLD) has been associated with subclinical cardiovascular
disease (CVD). This study was undertaken to evaluate the relationship between metabolic parameters, histologic
features and parameters of cardiac morphology and function in NAFLD subjects.
Methods: Nineteen non-diabetic, non-dyslipidemic, non-hypertensive patients with biopsy-proven NAFLD (17 men, age
41±8 years, BMI 26.8±3kg/m2) and 9 healthy controls (5 men, age 30±2 years, BMI 22.5±2kg/m2) underwent
transthoracic echocardiography and cardiac MRI to evaluate cardiac morphology and function. Endogenous glucose
production (EGP) and lipolysis were assessed by stable isotope tracers. Hepatic Insulin resistance (IR) as EGP x fasting
insulin, Oral Glucose Insulin Sensitivity (OGIS), adipo-IR as free fatty acids (FFAs) x fasting insulin were calculated.
Results: Despite the absence of diabetes, hypertension and overt dyslipidemia, NAFLD patients had significantly higher
concentration of FFAs than controls (p<0.05) and higher total saturated and monounsaturated levels (p<0.05). In NAFLD
basal Hepatic-IR (NAFLD vs controls: 92±34 vs 52±18 umol/min kg*mU/L) and Adipo-IR (NAFLD vs controls: 21±10 vs
11±5 mmol/L*mU/L) were significantly increased (p<0.03 for all NAFLD vs controls) and OGIS significantly reduced
(NAFLD vs controls: 11.0±1.64 vs 13.1±1.1 mg/kg min, p=0.005). The end-systolic LV diameter (30.4±3.7 vs 27.2±3.5
mm, p=0.044) was significantly higher in patients than in controls, suggesting subclinical systolic dysfunction. In NAFLD
patients, both hepatic-IR and adipo-IR directly correlated with MRI end-systolic LV volume (ESV) (r=0.63, p=0.004 and
r=0.54, p=0.018, respectively), while OGIS was inversely related to end-systolic LV diameter (r=-0.48, p=0.037) and ESV
(r=-0.48, p=0.036). At liver biopsy, steatosis ≥33% was associated with increased ESV (p=0.047), suggesting early
systolic dysfunction. Similarly, ESV was increased in patients with fibrosis (69.2±16.9 vs 94.5±31.4 cc, p=0.018), whereas
the ejection fraction (51±7 vs 59±7%, p=0.034) and cardiac index (2.9±0.7 vs 3.8±0.9, p=0.03) were significantly reduced.
Conclusions: In NAFLD subjects metabolic derangements and histological features are associated with subclinical
systolic LV dysfunction independent of diabetes, hypertension and dyslipidemia.
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